Molecular Drivers of Prostate Cancer Metastasis: Emerging Targets for Precision Therapy

Prostate cancer (PCa) stands as one of the primary cancer diseases affecting male health and represents the principal reason behind death when metastasis develops during late-stage disease. The spread of prostate cancer from its initial site demands intricate molecular interactions through signaling pathways which permit cancer cells to break their attachment to the original tumor mass and form secondary tumor sites in distant organs. Prostate cancer metastasis depends heavily on three main molecular pathways which include the PI3K/AKT signaling cascade along with Wnt/β-catenin pathway and epithelial-mesenchymal transition (EMT) signaling mechanisms. The deregulation of these signaling pathways creates strong contributions toward prostate cancer spread during metastasis and reduction of response to standard treatment methods. Presently available androgen deprivation therapy and chemotherapy have proven successful to some extent yet insufficient for effective treatment of both castration-resistant prostate cancer (CRPC) and metastatic disease. The development of therapies which block AKT signaling combined with Wnt signaling inhibition and reversal of EMT processes creates new treatment opportunities for better cancer outcome results. The combined use of immunotherapy with personalized medicine along with liquid biopsy technologies will improve therapeutic effects by enabling real-time tracking of disease evolution and treatment response. This analysis investigates the molecular processes that drive prostate cancer metastasis and the present therapeutic solutions and the upcoming therapies that try to block these pathways. Numerous treatment approaches and precision medicine strategies combining the integrated treatment approaches may lead to improved therapeutic benefit with fewer adverse effects while delivering more personalized and effective care. This review will majorly focus on the molecular pathways and preclinical treatment options that support metastatic prostate cancer, but briefly outline the clinical progress that is currently shaping the precision therapeutic models.